Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases
NCT ID: NCT06189820
Last Updated: 2024-01-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
70 participants
INTERVENTIONAL
2023-03-09
2027-03-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
NCT04362644
Functional and Structural Lung Imaging in Chronic Obstructive Pulmonary Disease
NCT04966221
Pulmonary Fibrosis During Severe COVID-19 Pneumonia
NCT04987528
To Evaluate the Use of Radiomics to Classify Between Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease
NCT04430491
Optimising Screening for Early Disease Detection in Familial Pulmonary Fibrosis
NCT05367349
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* before and after the initiation of an antifibrotic therapy (IPF or PPF) (cohort B)
* before and after the initiation of corticosteroid therapy in case of an acute exacerbation of ILD (cohort C)
* before and after the initiation of an immunosuppressive drug in the context of non-IPF pulmonary fibrosis (cohort D).
* before lung transplantation, surgery or biopsy to correlate with FAP expression determined by immunohistochemical analysis (IHC) (cohort E).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
SINGLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FAPI PET/CT
In the department of Nuclear Medicine:
* Installation in a relax chair after weight and height control
* Placement of a venous line in the upper limb after which an infusion of 500ml of 0.9% NaCl is started.
* Intravenous injection of 3 MBq/kg (max 300 MBq) of 18F- FAPI 74 or of 2 MBq/kg 68Ga-FAPI46
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study.
* Patients with an active lung neoplasm or any active neoplasm for blood samples
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Erasme University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medecine
Brussels, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P2022/587
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.